Table 1.

Patient and treatment characteristics

Characteristic		All patients	Locally advanced	Metastatic	p-value$
		(n = 50)	(n = 18)	(n = 32)
Age*		55 (49-66)	61 (48-67)	55 (50-61)	0.46**
Male		30 (60%)	10 (56%)	20 (63%)	0.77^
WHO PS
	0	34 (68%)	13 (72%)	21 (66%)	0.76^
	1	16 (32%)	5 (28%)	11 (34%)
Tumour location
	Head	30 (60%)	11 (61%)	19 (59%)	0.35#
	Uncinate	12 (24%)	6 (33%)	6 (19%)
	Body	5 (10%)	1 (6%)	4(13%)
	Tail	3 (6%)	0	3 (9%)
Biliary stent		22 (44%)	9 (50%)	13 (41%)	0.57^
Prior chemotherapy regime
	Gemcitabine first-line+	9 (18%)	2 (11%)	7 (22%)	0.39#
	Gemcitabine adjuvant	6 (12%)	1 (6%)	5 (16%)
Prior radiotherapy		1 (2%)	1 (6%)	0	0.36^
Pre-treatment surgery
	Bypass	6 (12%)	0	6 (19%)	0.06#
	PPPD/Whipple	6 (12%)	1 (6%)	5 (16%)
Number of cycles		8 ( 5-9)	8 (6-9)	8 (4-9)	0.40**
Dose modifications
	At start	7 (14%)	3 (17%)	4 (13%)	0.69^
	After the first cycle	38 (76%)	13 (72%)	25 (78%)
Surgical treatment
	Exploration without resection	1 (2%)	1 (6%)	0	0.002#
	Resection	1 (2%)	1 (6%)	0
	Radiofrequency ablation	2 (4%)	2 (11%)	0
	Irreversible electroporation	4 (8%)	4 (22%)	0
Second line therapy
	Gemcitabine monotherapy	8 (16%)	5 (28%)	3 (38%)	0.27#
	Capecitabine	1 (2%)	0	1 (3%)
	Gemcitabine based++	5 (10%)	0	5 (16%)
	Metformin plus everolimus	1 (2%)	0	1 (3%)

* at start of FOLFIRINOX treatment; ^$ Comparing LAPC and MPC; ** Mann-Whitney U test; ^ Fisher's Exact test; # Chi Square test; + Gemcitabine monotherapy in 3 patients (7%), combined with erlotinib in 3 patients (7%), with mTOR-inhibitor in 2 patients (4%) and with nab-paclitaxel in 1 patient (2%), ⁺⁺ gemcitabine combined with other chemotherapeutics or targeted agents